<document xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:z="http://www.ebi.ac.uk/z" source="Whatizit"><text><SENT sid="0" pm="."><plain>PURPOSE: This study was conducted to test the efficacy and toxicity of cetuximab and irinotecan as a biweekly regimen in treatment of elderly patients with <z:e sem="disease" ids="C0948380" disease_type="Neoplastic Process" abbrv="">metastatic colorectal cancer</z:e> (mCRC) </plain></SENT>
<SENT sid="1" pm="."><plain>PATIENTS AND METHODS: Forty-nine elderly patients (≥65 years) with mCRC who progressed after at least one previous line of treatment were enrolled into this study from May 2008 to January 2011 </plain></SENT>
<SENT sid="2" pm="."><plain><z:hpo ids='HP_0000001'>All</z:hpo> recruited patients received cetuximab 500 mg/m(2) and irinotecan 180 mg/m(2) every 2 weeks </plain></SENT>
<SENT sid="3" pm="."><plain>RESULTS: Thirty-seven patients (76 %) were men, and 76 % of patients had <z:e sem="disease" ids="C0007102" disease_type="Neoplastic Process" abbrv="">colonic cancer</z:e> in origin </plain></SENT>
<SENT sid="4" pm="."><plain>Median age was 69 years </plain></SENT>
<SENT sid="5" pm="."><plain>Median overall survival time was 7 months, and median progression-free survival was 4 months </plain></SENT>
<SENT sid="6" pm="."><plain>Grade 3-4 <z:hpo ids='HP_0000988'>skin rash</z:hpo> occurred in 20 % of patients, grade 3-4 <z:hpo ids='HP_0002014'>diarrhea</z:hpo> in 18 % of patients, and <z:hpo ids='HP_0001875'>neutropenia</z:hpo> in 28 % of patients </plain></SENT>
<SENT sid="7" pm="."><plain>CONCLUSION: Cetuximab combined with irinotecan when administered biweekly is safe and effective for treatment of pretreated elderly patients with mCRC </plain></SENT>
</text></document>